Ablynx NV, which discovers and develops fragment antibodies as therapies, said revenue in 2010 increased by 6% to €31.4 million primarily driven by milestone payments from Boehringer Ingelheim, which amounted to €11 million. ---Subscribe to MedNous to access this article--- Company News
